indazoles and kw 2449
indazoles has been researched along with kw 2449 in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Abe, A; Akinaga, S; Akiyama, T; Ishii, K; Ishikawa, Y; Kanda, Y; Kiyoi, H; Maeda, H; Minami, Y; Mori, Y; Naoe, T; Ozeki, K; Sato, Y; Shimizu, M; Shiotsu, Y; Tanizaki, R; Umehara, H | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Kiyoi, H | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Attkisson, E; Dai, Y; Grant, S; Jordan, N; Kolluri, N; Kramer, L; Muschen, M; Nguyen, N; Nguyen, T | 1 |
| Coumar, MS; Sarvagalla, S | 1 |
| Fuse, E; Hosogi, J; Kuwabara, T; Maeda, H; Ohashi, R; Tashiro, S; Yamamoto, Y | 1 |
| Fujita, K; Hosogi, J; Imamura, T; Kuwabara, T; Maeda, H; Ohashi, R; Ushiki, J; Yamamoto, Y | 1 |
| Liu, Y; Lyu, J; Miao, Z; Poon, TCW; Shim, JS; Tan, K; Wu, C; Yang, EJ; Zhang, B | 1 |
| Abbaspour, A; Afraei, S; Ahmadabad, HN; Azizi, G; Bagheri, Y; Di Fiore, MM; Goudarzvand, M; Hossein-Khannazer, N; Kamali, AN; Miladi, H; Panahi, Y; Tahmasebi, S; Yazdani, R | 1 |
| Cai, Z; Chen, G; Chen, X; Qin, X; Ren, W; Rui, C; Shi, SN; Wang, HY; Yu, J; Zhuang, C | 1 |
Reviews
2 review(s) available for indazoles and kw 2449
| Article | Year |
|---|---|
[FLT3 kinase inhibitors for the treatment of acute leukemia].
Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine | 2010 |
Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Topics: Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Binding Sites; Humans; Indazoles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Secondary; Pyrazoles | 2015 |
Other Studies
9 other study(ies) available for indazoles and kw 2449
| Article | Year |
|---|---|
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Indazoles; Isoleucine; K562 Cells; Leukemia; Male; Mice; Mice, Inbred C3H; Mice, SCID; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Threonine; Translocation, Genetic | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |
Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human.
Topics: Aldehyde Oxidase; Animals; Cytochrome P-450 Enzyme System; Dogs; Hepatocytes; Humans; Imines; Indazoles; Ions; Macaca fascicularis; Microsomes, Liver; Mitochondria; Monoamine Oxidase; Oxidation-Reduction; Piperazine; Piperazines; Rats | 2017 |
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins.
Topics: Aldehyde Oxidase; Animals; Carbon Isotopes; Humans; Indazoles; Macaca fascicularis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Pargyline; Piperazines; Protein Binding; Proteins; Radioligand Assay; Sodium Cyanide | 2018 |
PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; HCT116 Cells; Humans; Indazoles; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Anti-Inflammatory Effect of KW-2449 on Autoimmune Encephalomyelitis: An Experimental Study on Mice.
Topics: Animals; Anti-Inflammatory Agents; Brain; Chemotaxis, Leukocyte; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Indazoles; Inflammation Mediators; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Piperazines | 2021 |
The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Dose-Response Relationship, Drug; Drug Delivery Systems; HT29 Cells; Humans; Indazoles; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Necroptosis; Piperazines; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases | 2021 |